Redeye comments on Cantargia's third quarter report and events after the end of the quarter, includi...
Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its pr...
With activity picking up from mid-September onwards, as expected, we are optimistic about Raketech's...
Redeye retains its positive view on Vertiseit following a solid Q3, with margins beating our forecas...
The 3rd of November, Eevia Health (“Eevia” or “the company”) announced that the company has develope...
Redeye states that Q3 revenues are still not satisfactory but that it’s good that the burn rate is k...
Redeye is surprised to see the strong recovery in gross margins in Q3.
Redeye sees good progress in the third quarter, although we had hoped for even a little bit more.
Redeye comments on the events of the third quarter, including progress with the main candidate Pulmo...
Bra organisk tillväxt Organisk tillväxt var 8% i Q3 (2% i Q3'21 och 6% i Q2'22).
Omsättning och EBITDA i linje med våra estimat Omsättningen uppgick till EUR 22.
Sales up 24%, EBIT down 29% Sales, EBIT 6% and 26% lower than our expectations Guidance maintained ...
I dag offentliggjorde Angler Gaming sin delårsrapport för det tredje kvartalet 2022.
Smart High Tech publicerade den 8 november 2022 bolagets delårsrapport för tredje kvartalet 2022.
Redeye comments on QleanAir’s Q3 figures, with sales and EBITDA slightly below estimates.
Redeye states Gasporox report was strong with beats accross the board.
We lower ’23e EBIT by 4% Negatively affected by hedge prices The share is trading at ~6x P/E on 2023...
Sales & adj. EBIT above our expectations We cut adj.
Redeye states that the quarterly financials were more or less in line with expectations, and we only...
Solid customer intake but sequential margin contraction We cut ‘22e-‘24e EBITDA by 3-6% 12x-11x ‘22e...
